cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Ionis Pharmaceuticals Inc
8 own
25 watching
Current Price
$40.78
$-0.13
(-0.32%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
5,956.89M
52-Week High
52-Week High
54.44000
52-Week Low
52-Week Low
34.32000
Average Volume
Average Volume
0.4M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
106.6829
iconMarket Capitalization5,956.89M
icon52-Week High54.44000
icon52-Week Low34.32000
iconAverage Volume0.4M
iconDividend Yield--
iconP/E Ratio106.6829
What does the Ionis Pharmaceuticals Inc do?
Isis Pharmaceuticals, Inc. engages in the discovery and development of antisense drugs using novel drug discovery platform. The company's flagship product includes the KYNAMRO injection, which is an apo-B synthesis inhibitor for patients with...
Read More
How much money does Ionis Pharmaceuticals Inc make?
News & Events about Ionis Pharmaceuticals Inc.
PR Newswire
9 months ago
Ionis to present at upcoming investor conference Ionis to present at upcoming investor conference PR Newswire CARLSBAD, Calif., July 5, 2023 CARLSBAD, Calif., July 5, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in a fireside chat...
Zolmax
11 months ago
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS Get Rating) Analysts at SVB Leerink raised their FY2024 earnings per share estimates for shares of Ionis Pharmaceuticals in a report issued on Tuesday, April 25th. SVB Leerink analyst M. Foroohar now expects that the company will post earnings of ($3.93) per ...
PR Newswire
1 year ago
New data presented at AD/PD2023 show IONIS-MAPT Rx (BIIB080) substantially reduced tau protein in patients with early-stage Alzheimer's disease New data presented at AD/PD2023 show IONIS-MAPT Rx (BIIB080) substantially reduced tau protein in patients with early-stage Alzheimer's disease PR Newswire...
PR Newswire
1 year ago
Ionis reports positive topline 66-week results of eplontersen Phase 3 study for patients with ATTRv-PN Ionis reports positive topline 66-week results of eplontersen Phase 3 study for patients with ATTRv-PN PR Newswire CARLSBAD, Calif., March 27, 2023 Eplontersen met co-primary endpoints...
PR Newswire
1 year ago
Ionis accounces FDA advisory committee voted unanimously for a potential accelerated approval of tofersen for SOD1-ALS Ionis accounces FDA advisory committee voted unanimously for a potential accelerated approval of tofersen for SOD1-ALS PR Newswire CARLSBAD, Calif., March 22, 2023 If approved...
Frequently Asked Questions
Frequently Asked Questions
What is Ionis Pharmaceuticals Inc share price today?
plus_minus_icon
Can Indians buy Ionis Pharmaceuticals Inc shares?
plus_minus_icon
How can I buy Ionis Pharmaceuticals Inc shares from India?
plus_minus_icon
Can Fractional shares of Ionis Pharmaceuticals Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Ionis Pharmaceuticals Inc stocks?
plus_minus_icon
What is today’s traded volume of Ionis Pharmaceuticals Inc?
plus_minus_icon
What is today’s market capitalisation of Ionis Pharmaceuticals Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Ionis Pharmaceuticals Inc?
plus_minus_icon
What percentage is Ionis Pharmaceuticals Inc down from its 52-Week High?
plus_minus_icon
What percentage is Ionis Pharmaceuticals Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$40.78
$-0.13
(-0.32%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00